top of page

History and milestone

Buffalo Biotech is a preclinical stage company that provides a novel lung lavage therapy called the "Vigor Solution" for Acute Respiratory Distress Syndrome (ARDS). The company has pioneered a unique physical treatment method to address the non-pharmacological challenges of ARDS. The "Vigor Solution" utilizes a non-specific adsorption method to effectively reduce pulmonary cytokines. Safety assessments conducted on small pig lungs after administering the "Vigor Solution" for 168 days showed it to be harmless.

Severe ARDS animal studies demonstrated a 25% reduction in PMNL infiltration, a 25% reduction in pulmonary edema, and a 50% decrease in mortality rates. Buffalo Biotech is currently seeking funding to support collaborations with doctors and provide compassionate treatment for ARDS patients. The "Vigor Solution" can be used not only for typical ARDS cases but also for COVID-19 related ARDS.

2020

Start-up company. In light of the COVID-19 pandemic, Buffalo biomedical technology co. Ltd. established to develop novel treatments for acute respiratory distress (ARDS) caused by COVID-19 induced cytokine storm.

2021

VIGOR lung solution idea was proof of concept.

The safety andEfficacy animal study demonstrate VIGOR lung solution is safety and efficitaly to treat LPS induced acute lung injury in SD-rats.

Application PCT patent.

First GMP like batch.

2022

Class III medical device (Taiwan)

Three kinds of animal trials demonstrate harmless and efficiency(therapeutic efficacy test, subacute systemic toxicity assessment, and long-term minipig biocompatibility study)

2023

Compassionate use(in progress)

3 GMP manafacture batches 

2024

ISO 10993 and QMS license
IDE approval
Phase I/IIa Study to Evaluate Efficacy and Safety of Vigor Solution in Acute respiratory distress syndrome (ARDS) (12 patients)

2025-2026

Phase II Study (Site: Taiwan, US or AU)

2027

Product launch in TW

bottom of page